OncoMatch/Clinical Trials/NCT03937544
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
Is NCT03937544 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including CD19 CAR-T CELLS and Cyclophosphamide for relapsed b acute lymphoblastic leukaemia.
Treatment: CD19 CAR-T CELLS · Cyclophosphamide · Fludarabine — This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Cannot have received: immunotherapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Cannot have received: allogeneic cellular therapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Cannot have received: anti-GVHD therapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Lab requirements
Kidney function
creatinine clearance > 50 ml/min
Liver function
serum total bilirubin < 5 times the normal value
Cardiac function
left ventricular ejection fraction > 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify